Elizabeth Pickup

Elizabeth Pickup

Auto-generated profile, based on publicly available information

Elizabeth Pickup

Division of Neurology, Children's National Hospital, Washington, District of Columbia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in Pediatric Neurology
Verified
Journal Article
Closed access
EPElizabeth E.S. Pickup
Elizabeth E.S. Pickup
SSSarah D. Schlatterer
Sarah D. Schlatterer
APAdre J. du Plessis
Adre J. du Plessis
SMSarah B. Mulkey
Sarah B. Mulkey

12 April 2024 in Pediatric Neurology
Verified
Journal Article
Closed access
EPElizabeth Pickup
Elizabeth Pickup
SMSteven A. Moore
Steven A. Moore
PSPim Suwannarat
Pim Suwannarat
CGChristina Grant
Christina Grant
NMNicholas Ah Mew
Nicholas Ah Mew
KSKuntal Sen
Kuntal Sen

3 June 2024 in Annals of the Child Neurology Society
Verified
Journal Article
Open access
EPElizabeth Pickup
Elizabeth Pickup
CRChristopher Redmond
Christopher Redmond
MSMatthew A. Sherman
Matthew A. Sherman
LNLakshmi Ramachandran Nair
Lakshmi Ramachandran Nair
SSSangeeta Sule
Sangeeta Sule
AKAlexandra B. Kornbluh
Alexandra B. Kornbluh
Objective: Overlap syndromes have been described between N‐methyl‐ d‐aspartate receptor encephalitis (NMDARE) and other neuroinflammatory conditions, although rarely involving neurosarcoidosis. Molecularly targeted immunotherapy may be helpful in the empiric treatment of these conditions.Methods: We describe a 9‐year‐old boy with new‐onset seizures and worsening encephalopathy.Results: Initial evaluation was concerning for neurosarcoidosis, including elevated cerebrospinal fluid (CSF) and serum angiotensin‐converting enzyme and leptomeningeal with multiple cranial nerve enhancement on magnetic resonance imaging. CSF and serum cytokine profiles were used to choose targeted empiric immunotherapy, and the boy's seizure burden and encephalopathy improved after treatment with tocilizumab. The NMDA receptor antibody titer was later found to be elevated, raising suspicion for a novel overlap syndrome.Interpretation: Our patient met the criteria for definite NMDARE and possible neurosarcoidosis. Given the mixed radiographic and serologic markers in this child, cytokine levels were used to direct the choice of empiric treatment, resulting in excellent clinical response. This case suggests that targeted immunotherapy informed by cytokine testing may be helpful in cases of high‐acuity pediatric neuroinflammatory disease with limited diagnostic clarity.

12 October 2024 in Pediatric Neurology
Verified
Journal Article
Closed access
EPElizabeth Pickup
Elizabeth Pickup
KSKyle Spagnolo
Kyle Spagnolo
AKAlexandra B. Kornbluh
Alexandra B. Kornbluh

19 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
EPElizabeth Pickup
Elizabeth Pickup
MAMerve Ozge Aktop
Merve Ozge Aktop
EMEmily McCracken
Emily McCracken
AKAlana Kravitz
Alana Kravitz
JBJames E. Bost
James E. Bost
JSJeffrey Strelzik
Jeffrey Strelzik
Background: Peripheral nerve blocks (PNBs), while an effective treatment of headache disorders in adults, have been infrequently studied in pediatric patients. This study aimed to assess practice patterns in PNB use in pediatric headache.Methods: This was a prospective study conducted between 2020 and 2022 in a headache clinic at a tertiary children’s hospital. Pre- and post-injection survey data were prospectively obtained from 16 patients over 32 visits where PNBs, including greater and lesser occipital, auriculotemporal, supraorbital, and supratrochlear nerve blocks, were administered.Results: Participants ranged in age from 10 to 19 years old, with a median age of 16.7 years, and the majority were diagnosed with migraine without aura. Among the total cohort, mean pain scores, obtained on a 10-point scale, decreased from 4.4 pre-injection to 2.8 post-injection (p=0.003). When stratified by specific headache diagnosis, only patients with migraine without aura reported significant pain decrease (p=0.007).Conclusion: These preliminary findings support that PNBs may be a promising treatment in pediatric headache, particularly in migraine without aura.

29 May 2026 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
EPElizabeth Pickup
Elizabeth Pickup
MTMrinmayee Takle
Mrinmayee Takle
RLRaquel Langdon
Raquel Langdon